Zurich Cantonal Bank
DSGN icon

Zurich Cantonal Bank’s Design Therapeutics DSGN Stock Holding History

Zurich Cantonal Bank’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.8K Buy
3,025
+1,431
+90% +$17.8K ﹤0.01% 2454
2026
Q1 		$17K Buy
1,594
+367
+30% +$3.71K ﹤0.01% 2463
2025
Q4 		$11.5K Hold
1,227
– – ﹤0.01% 2479
2025
Q3 		$9.24K Sell
1,227
-590
-32% -$2.96K ﹤0.01% 2503
2025
Q2 		$6.12K Sell
1,817
-348
-16% -$1.3K ﹤0.01% 2532
2025
Q1 		$8.36K Buy
+2,165
New +$10.3K ﹤0.01% 2599
2024
Q2 		– Sell
-1
Closed -$4 – 2661
2024
Q1 		$4 Hold
1
– – ﹤0.01% 2705
2023
Q4 		$3 Hold
1
– – ﹤0.01% 2724
2023
Q3 		$2 Hold
1
– – ﹤0.01% 2786
2023
Q2 		$6 Hold
1
– – ﹤0.01% 2792
2023
Q1 		$6 Sell
1
-1,114
-100% -$8.33K ﹤0.01% 2849
2022
Q4 		$11.4K Sell
1,115
-214
-16% -$2.9K ﹤0.01% 2798
2022
Q3 		$22K Hold
1,329
– – ﹤0.01% 2777
2022
Q2 		$19K Sell
1,329
-119
-8% -$1.61K ﹤0.01% 2801
2022
Q1 		$23K Buy
+1,448
New +$22.2K ﹤0.01% 2655

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Zurich Cantonal Bank's DSGN Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Design Therapeutics (DSGN) stake by 90% in Q2 2026, buying an estimated $17.8K and bringing the position to 3,025 shares worth $43.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2454.

Zurich Cantonal Bank first reported a position in DSGN in Q1 2022 and has held it in 15 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Zurich Cantonal Bank held 3,025 shares of Design Therapeutics worth $43.8K as of Q2 2026.
  • Zurich Cantonal Bank bought 1,431 Design Therapeutics shares in Q2 2026, an estimated $17.8K.
  • Design Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2454 holding.
  • Zurich Cantonal Bank first reported a position in Design Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.